Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 32598

Reviews
Table of Contents - Year : 2017 | Month : May | Volume : 11 | Issue : 5 | Page : DE01 - DE04

Ebola Vaccine: How Far are we? DE01-DE04

Rajani Sharma, Ketki Jangid, Anuradha

Correspondence
Dr. Rajani Sharma,
Senior Resident, Department of Microbiology, PGIMER and Dr. Ram Manohar Lohia Hospital, New Delhi, India.
E-mail: rajanidhaundiyal@gmail.com

Ebola viruses have been identified as an emerging threat as it causes severe haemorrhagic fever in human with mortality rates ranging from 50 to 90%. In addition to being a global health concern, the virus also is considered a potential biological threat agent. As for now, no licensed vaccine is available for pre or post exposure treatment. Recent epidemic of this disease in South Africa has led to concern towards development of an effective vaccine on a priority basis. This review is an attempt to look upon current progress in the development of Ebola virus vaccines and highlights strategies that have the greatest potential for commercial development.